Global radiotherapy industry to 2027

Global radiotherapy industry to 2027

DUBLIN, November 9, 2022 /PRNewswire/ — The “Global Radioisotope Radiotherapy Market, Application, End User and Region: Competition Forecast and Opportunities to 2027” Report has been added to ResearchAndMarkets.com offering.


The global radiotherapy market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for combined imaging and therapeutic agents. It is a systematic integration of specific diagnoses and treatments.

The increasing prevalence of cancer and the growing adoption of injectable radiopharmaceuticals that have antitumor effects are greatly contributing to the growth of the global radiotherapy market. The increasing use of radiation theranostics in cancer diagnosis and treatment is driving the market. Radiotheranostics have improved the efficacy of therapy, the ability to handle adverse and critical health situations, which translates into better results for patients.

Furthermore, recent research and developments in the field of radiotherapy are generating a positive impact on the growth of the market. For example, there have been important results in radiation therapy for prostate cancer and neuroendocrine tumors. In addition, regulatory approval of numerous pairs of radiotheranostics is expected to drive their adoption for cancer treatments.

For example, the approvals of new radiotheranostic agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in a resurgence of research in the field of radiotherapy and have proliferated the number of clinical trials and tests of other novel radiotherapies.

Additionally, ongoing research and development support to keep up with the current momentum in radiotheranostics innovations is supporting market growth. In addition, the clinical use of radiotheranostic agents has increased dramatically due to successful advances in understanding the underlying biology of cancer and improved methods for synthesizing and designing targeted theragnostic agents. This, in turn, positively influences the growth of the market.

Structural imaging is the most crucial component of staging, diagnosis, and response evaluation in cancer patients. However, patients and healthcare professionals are increasingly seeking noninvasive methods to investigate tumor phenotypes and assess molecular and functional responses to therapy. Therefore, radiotherapy, a combination of non-invasive diagnostic imaging with targeted therapy, is being widely implemented. As a result, the global radiotheranostics market is anticipated to drive at a fast pace in the coming years.

Market segmentation

The global radiotherapy market is segmented by radioisotope, application, end user, competitive landscape, and regional distribution. Depending on the radioisotope, the market differentiates between technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64 and others. Due to supply, the market is fragmented between oncology and non-oncology.

The oncology segment further branches into thyroid cancer, neuroendocrine cancer, hepatocellular carcinoma, multiple myeloma and lymphoma, and others. The non-oncology applications segment is further divided between joint infections, arthritis, bone pain and others.

On the basis of end user, the global market is segmented into hospitals and clinics, pharmaceutical and biotech companies, and others. The market analysis also studies the regional segmentation to devise the regional market segmentation, divided between North America, Europe, Pacific AsiaMiddle East and Africa, South America.

Company Profile

TransCode Therapeutics, Inc., Curium SAS, GE Healthcare Inc., Bayer AG, Lantheus Medical, Imaging, Inc., Novartis AG, Spectrum Pharmaceuticals, Inc., Ipsen SA, Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, and Boston Scientific Corporation are the major market players responsible for the growth of the global radiotherapy market.

Key Topics Covered:

1. Product Overview

2. Research methodology

3. Executive Summary

4. Impact of COVID-19 on the global radiotherapy market

5. Voice of the Customer
5.1. Radiation Therapeutics Awareness
5.2. Cancer prevalence, by gender
5.3. Cancer prevalence, by age group
5.4. Cancer Prevalence, Region
5.5. Benefits of the use of radiotheranostics

6. Analysis of clinical trials

7. Patent Analysis

8. Global Radiotherapy Market Outlook
8.1. Market size and forecast
8.1.1. by value
8.2. Market share and forecast
8.2.1. By radioisotope (technetium-99, gallium-68, iodine-131, iodine-123, 18F, Y-90Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Others)
8.2.2. By application (oncology vs. non-oncology)
8.2.2.1. Oncology Applications (Thyroid Cancer, Neuroendocrine Cancer, Hepatocellular Carcinoma, Multiple Myeloma and Lymphoma, Others)
8.2.2.2. Non-Oncological Applications (Joint Infections, Arthritis, Bone Pain, Others)
8.2.3. By end user (hospitals and clinics, pharmaceutical and biotech companies, others)
8.2.4. By region
8.2.5. By company (2021)
8.3. Product Market Map

9. North American Radiotherapy Market Outlook

10. Outlook for the European radiotherapy market

11. Asia-Pacific Radiotherapy Market Outlook

12. Prospects for the radiotherapy market in South America

13 middle East and Africa Radiotherapy Market Outlook

14. Market dynamics
14.1. drivers
14.2. challenges

15. Market trends and developments

16. SWOT Analysis: Global Radiotherapy Market

17. Competitive landscape (including SWOT analysis of profiled players)
17.1. TransCode Therapeutics, Inc.
17.2. Curio SAS
17.3. GE Healthcare Inc.
17.4. Bayer AG
17.5. Lantheus Medical Imaging, Inc.
17.6. Novartis AG
17.7. Spectrum Pharmaceuticals, Inc.
17.8. Ipsen SA
17.9. Actinium Pharmaceuticals, Inc. (ATNM)
17.10. Nordic Nanovector ASA
17.11. Y-mAbs Therapeutics, Inc.
17.12. Sofie Biosciences, Inc.
17.13. Terumo Corporation
17.14. Limited Medical Sirtex
17.15. Boston Scientific Corporation

18. Strategic recommendations

For more information on this report, visit https://www.researchandmarkets.com/r/4vvn9q

Media Contact:

Research and Markets
laura woodSenior manager
[email protected]

For business hours EST call +1-917-300-0470
For US/Canada call toll free +1-800-526-8630
For GMT business hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Leave a Comment